Moderna, Inc. (NASDAQ:MRNA) had the biggest day in its history Wednesday. The bill arrived Thursday morning.

The stock handed back as much as 25.69%, eyeing the worst session in company’s history.

On Wednesday, Moderna shares closed up 176.97%, a record, after the biotech company and Merck & Co., Inc. (NYSE:MRK) reported positive late-stage results for intismeran autogene, a cancer vaccine built from the mutations found in each patient’s own tumor.

It is the first mRNA cancer therapy to clear a Phase 3 trial, the final testing stage before regulators decide.

Yet, Moderna was one of the most shorted names in the market, with short interest at about 12.5% of float.

Photo: Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.